Printer Friendly

A. L. LABORATORIES OBTAINS RIGHTS TO UNIQUE CONTROLLED RELEASE TECHNOLOGIES

 FORT LEE, N.J., March 31 /PRNewswire/ -- A. L. Laboratories, Inc. (NYSE: BMD) today announced that it has obtained exclusive rights to a patented, unique technology for the delivery to and absorption of drugs in the colon. The technology was discovered jointly by scientists at The Hebrew University and Perio Products, Ltd., both located in Jerusalem, Israel. Perio Products is currently developing the colonic delivery technology. In addition to the exclusive rights obtained, A. L. Laboratories has taken a minority share position in Perio Products. The major shareholder of Perio Products, Ltd. is Israel Chemicals Ltd. (ICL), which is one of Israel's largest industrial groups, with more than $1 billion in annual revenue. Terms of the transaction were not disclosed.
 Controlled release technology specifically targeted for colonic delivery and/or absorption of pharmaceuticals, is widely viewed as one of the last remaining opportunities in human medicine for improving drug delivery. Several current therapies could be dramatically enhanced by delivery in the colon because of long residence time and high absorptive capability. The technology acquired will be the basis for research and development of products targeted to the treatment of diseases of the colon such as Crohn's disease, Irritable Bowel Disorder, ulcerative colitis and colon carcinoma. A. L. Laboratories' research executives will be members of a Scientific Review Committee that will plan and monitor the research and development based on an agreed upon plan. A. L. Laboratories will be responsible for regulatory activities leading to New Drug Applications (NDAs) or equivalents in other countries to obtain marketing approvals, and will have exclusive worldwide marketing rights to products commercialized from this technology. An initial expenditure of $5 million has been committed to optimize and develop colonic delivery products from this new technology.
 Jeffrey E. Smith, executive vice president of A. L. Laboratories, Inc. said, "For a number of years we have sought to bring into our Company innovative controlled release technologies that would lend themselves to the development of unique, proprietary pharmaceuticals using known active ingredients. This technology is particularly attractive because we believe it has broad application for the treatment of diseases of the colon. It also has potential value for the treatment of other diseases via absorption in the colon using drugs that currently are degraded or destroyed in the stomach and small intestine. Utilization of this technology could allow for the use of much lower doses of such drugs and thereby eliminate or reduce side effects compared to current treatment methods. Large potential applications exist to the extent that polypeptides and proteins (such as insulin) can be absorbed from the colon. Steroids, a current treatment of colon diseases, require doses which commonly result in serious side effects. Delivery of steroids targeted to the colon would allow lower doses with fewer side effects, and be equally or more effective. We look forward to working on an aggressive research program in this relatively untapped area of pharmaceutical medicine."
 Exclusive marketing rights for two other controlled release technologies were also obtained: a versatile patented liquid polymer, and a controlled release polymer in film form. Perio Products has commercialized a number of products for oral health care using these two technologies, and has three products undergoing clinical trials in the United States and Europe. A. L. Laboratories' exclusive worldwide rights encompass specific oral health care and all non-oral health care products derived from these technologies. As part of the arrangement, the Company will also have access to marketing existing oral health care products or those developed in the future by Perio Products.
 A. L. Laboratories is a multinational manufacturer and marketer of specialty and value-added, branded pharmaceuticals and animal health micronutrients, with plant sites in Illinois, Maryland, New Jersey, New York, North Carolina, Washington State, Denmark and Indonesia.
 -0- 3/31/93
 /CONTACT: Iris Daniels of A. L. Laboratories, 201-947-7774; or David Walke of Morgen-Walke Associates, 212-986-5900, for A. L. Laboratories/
 (BMD)


CO: A. L. Laboratories, Inc. ST: New Jersey IN: HEA SU:

LR -- NY008 -- 1354 03/31/93 08:53 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 31, 1993
Words:669
Previous Article:DEVRY REPORTS 10.9 PERCENT INCREASE IN SPRING TERM NEW STUDENT ENROLLMENT
Next Article:BOVINE GROWTH HORMONE WOULD ONLY COMPOUND PROBLEMS OF SICK U.S. DAIRY HERD, FACT TELLS FDA VETERINARY COMMITTEE
Topics:


Related Articles
A. L. LABORATORIES STUDIES BUSINESS COMBINATION WITH APOTHEKERNES LABORATORIUM
A. L. LABORATORIES ANNOUNCES KEY MANAGEMENT APPOINTMENTS AT ITS BARRE-NATIONAL SUBSIDIARY
A. L. LABORATORIES, INC. ANNOUNCES ACQUISITION
A. L. LABORATORIES ANNOUNCES FIRST APPROVAL FOR ITS DENTURE STOMATITIS TREATMENT PRODUCT
A. L. LABORATORIES NAMES CYRILL SIEWERT AS ORAL HEALTH CARE PRESIDENT
A. L. LABORATORIES REPORTS FIRST QUARTER EARNINGS
A. L. LABORATORIES NAMES BETH POSNACK HECHT AS CORPORATE COUNSEL
A. L. LABORATORIES NAMES JIM FLYNN VICE PRESIDENT, CORPORATE DEVELOPMENT
Carrington's Research Wins International Aloe Science Council Award.
Carrington subsidiary DelSite granted Korean patent for GelSite polymer technology.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters